Text Size

Evaluation of Surfactant Protein B in the Differential Diagnostics of Dyspnea

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2010 by University Hospital Mannheim.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Roche Diagnostics AG, Switzerland
Information provided by:
University Hospital Mannheim
ClinicalTrials.gov Identifier:
NCT01197586
First received: September 8, 2010
Last updated: June 18, 2012
Last verified: September 2010
History of Changes
  Purpose

Establishing new biochemical markers in the differential diagnostics and risk stratification in heterogeneous patient collectives is becoming more and more important. The markers should be objective, reliable, reproducible, quick and cost effective as well as specific and sensitive. Concerning the differential diagnostics of "dyspnea", NT-pro-BNP plays the most important role for the evaluation of a cardiac origin. However, a corresponding biochemical marker for pulmonary stress is lacking. The aim of the study at hand therefore was the evaluation of surfactant protein B in the differential diagnostics of pulmonary and cardiac diseases.


Condition
Dyspnea
Cardiac Disease
Pulmonary Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University Hospital Mannheim:

Estimated Enrollment: 60
Study Start Date: October 2010
  Eligibility

Ages Eligible for Study:   50 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

patients presenting with the symptom "dyspnea" in a university hospital emergency room

Criteria

Inclusion Criteria:

  • patients presenting with dyspnea and giving informed consent

Exclusion Criteria:

  • outpatients
  • lack or doubt of legal competence
  • indication for mechanical ventilation
  • pregnancy
  • palliative patients
  • CPAP/LTOT
  • BMI > 27 kg/m2
  • sepsis
  • anemia
  • dialysis
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01197586

Locations
Germany
Universitaetsmedizin Mannheim
Mannheim, Germany, 68167
Sponsors and Collaborators
University Hospital Mannheim
Roche Diagnostics AG, Switzerland
  More Information

No publications provided

Responsible Party: Dr. J. Saur, Universitaetsmedizin Mannheim
ClinicalTrials.gov Identifier: NCT01197586     History of Changes
Other Study ID Numbers: 2010_spb_ma
Study First Received: September 8, 2010
Last Updated: June 18, 2012
Health Authority: Germany: Ethics Commission

Keywords provided by University Hospital Mannheim:
surfactant protein B
differential diagnostics

Additional relevant MeSH terms:
Dyspnea
Heart Diseases
Lung Diseases
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms, Respiratory
 Signs and Symptoms
Cardiovascular Diseases
Pulmonary Surfactants
Respiratory System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 17, 2013